Organization | Eugonia

Eugonia Report issue

Academic/Hospital Phase 4

Founded: Athens Greece (1988)

Organization Overview

First Clinical Trial

2003

NCT00417066

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Alternative names

Eugonia | Eugonia IVF Unit, Athens, Greece

Active Ingredients

Drugs in Phase 4 Trials (7)

corifollitropin alfa (1 trial)

follitropin beta (Follistim) (1 trial)

ganirelix (3 trials)

gonadorelin (factrel) (1 trial)

recombinant human choriogonadotropin alfa (Ovidrel) (2 trials)

triptorelin (Trelstar) (4 trials)

urinary human chorionic gonadotrophin (1 trial)

Drugs in Other Trials (1)

cetrorelix (cetrotide) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Infertility (Phase 4)

Menopause, Premature (Phase 4)

Ovarian Hyperstimulation Syndrome (Phase 4)

Polycystic Ovary Syndrome (Phase 4)

Primary Ovarian Insufficiency (Phase 4)

Syndrome (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 8